Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025)

Tg Therapeutics has reported Long-Term Deferred Tax over the past 1 years, most recently at $348.0 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $348.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $348.0 million (changed N/A YoY), and the annual figure for FY2025 was $348.0 million, changed.
  • Long-Term Deferred Tax for Q4 2025 was $348.0 million at Tg Therapeutics, down from $366.6 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for TGTX hit a ceiling of $366.6 million in Q3 2025 and a floor of $348.0 million in Q4 2025.